Drug Enforcement Administration (DEA) officials have proposed reclassifying marijuana (or cannabis) as a Schedule Three drug. Despite a majority of states having legislation allowing for medicinal and recreational use, marijuana it still classified as a Schedule One narcotic along with heroin.

Curaleaf (CURLF) CEO Matt Darin sits down with Catalysts Hosts Seana Smith and Madison Mills to talk about how long cannabis businesses has been waiting for a change like this and what it signifies for the future of the industry and the SAFE Banking Act.

"It's a long time coming, but I think the findings are really backed in science and backed under a very detailed review that the government did to evaluate the medicinal benefits of cannabis," Darin says, "and that it truly does belong as a Schedule Three, a substance versus Schedule One on par with things like heroin and fentanyl which all Americans have known for quite some time, just was not right."

For more expert insight and the latest market action, click here to watch this full episode of Catalysts.

This post was written by Luke Carberry Mogan.